AVANIR Subsidiary Xenerex Biosciences and Peregrine Pharmaceuticals Announce Research Collaboration for Solid Tumor Cancer Antibody Therapeutics
(PR Newswire)...human monoclonal antibody therapies for the treatment of solid tumor cancers.......commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its ``collateral targeting technologies``......., is currently being studied in the U.S. in a Phase II trial for brain cancer and five Phase I trials for colorectal, pancreatic, bilia...- Jun 12 7:02 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010612/latu072.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines